Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Solid Tumors × Antiemetics × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 1 Multiple Myeloma 1 Advanced Solid Tumors 1

Interventions

Injections 6 Bevacizumab 5 pembrolizumab 4 Paclitaxel 4 Leucovorin 4 Fluorouracil 4 trifluridine tipiracil drug combination 3 Oxaliplatin 3 Irinotecan 3 Docetaxel 3 Carboplatin 3 Capecitabine 3 toripalimab 2 tislelizumab 2 Pemetrexed 2 Nivolumab 2 Gemcitabine 2 Fulvestrant 2 Cisplatin 2 BMS-753493 2 130-nm albumin-bound paclitaxel 2 urelumab 1 ulixertinib 1 palbociclib 1 mogamulizumab 1 lenvatinib 1 fluzoparib 1 fludarabine 1 duvelisib 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06242691 2026-03-06

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡